DoseVault
Metabolic Compound

Survodutide

Investigational GLP-1 / glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma.

Scientific Overview

Survodutide (BI 456906) is a weekly GLP-1R / glucagon-receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 in obesity reported up to 19% weight loss at 46 weeks, and a 2024 MASH trial demonstrated significant fibrosis improvement. Phase 3 SYNCHRONIZE program is ongoing.

Key Research Benefits

  • ✓Strong weight loss (~19% Phase 2)
  • ✓MASH liver-fat reduction
  • ✓Glucose control

Potential Side Effects

⚠GI side effects (dose-limiting)
⚠Increased heart rate
⚠Injection-site reactions

Research Protocols

Common Dosages

Investigational

0.6 -> 4.8 mg
Weekly SC

“Phase 3 dosing”

Note: Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Dose Calculator

🧮 Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

24 Units

or 0.24 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Explore Survodutide

Where to source

Vendors with public COAs that stock this category. Affiliate links are disclosed.

  • Limitless Life Nootropics
    FL-based research-peptide supplier with Janoshik third-party COAs and a public affiliate program at ~20%.
    COA: JanoshikAffiliate disclosed
    View vendor →
  • SwissChems
    60+ peptide catalog with Janoshik COAs; weekly affiliate payouts.
    COA: JanoshikAffiliate disclosed
    View vendor →
  • Amino Club
    EU/US-facing vendor with a 20% first-order / 10% recurring affiliate model.
    COA: Third-partyAffiliate disclosed
    View vendor →

Survodutide by goal

Read Survodutide's profile filtered through specific research goals.

Survodutide for Fat Loss

Molecular Profile

linear
modified glucagon/GLP-1
30 AA Sequence

Quick Reference

Status
Research Compound
Category
Metabolic
Common Dosage
0.6 -> 4.8 mg
Weekly SC

Strictly for research purposes. Not for human consumption.

Related tools

Medical Disclaimer

Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.